[1]
Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153-65.
[2]
Boeck C. Multiple benign sarcoid of the skin. J Cutan Genitourin Dis 1899; 17: 543-50.
[3]
Chokoeva AA, Tchernev G, Tana M, Tana C. Exclusion criteria for sarcoidosis: A novel approach for an ancient disease? Eur J Intern Med 2014; 25(10): e120.
[4]
Tana C, Wegener S, Borys E, et al. Challenges in the diagnosis and treatment of neurosarcoidosis. Ann Med 2015; 47(7): 576-91.
[5]
Brauner MW, Grenier P, Mompoint D, Lenoir S, de Crémoux H. Pulmonary sarcoidosis: Evaluation with high-resolution CT. Radiology 1989; 172(2): 467-71.
[6]
Müller NL, Kullnig P, Miller RR. The CT findings of pulmonary sarcoidosis: Analysis of 25 patients. AJR Am J Roentgenol 1989; 152(6): 1179-82.
[7]
Nishimura K, Itoh H, Kitaichi M, Nagai S, Izumi T. CT and pathological correlation of pulmonary sarcoidosis. Semin Ultrasound CT MR 1995; 16(5): 361-70.
[8]
Xaubet A, Ancochea J, Morell F, et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21(1): 64-70.
[9]
Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974; 57(6): 847-52.
[10]
Bottaro L, Calderan L, Dibilio D, Mosconi E, Maffessanti M. Pulmonary sarcoidosis: Atypical HRTC features and differential diagnostic problems. Radiol Med 2004; 107(4): 273-85.
[11]
Miller BH, Rosado-de-christenson ML, Mcadams HP, et al. Thoracic sarcoidosis: Radiologic-pathologic correlation. Radiographics 1995; 15(2): 421-37.
[12]
Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol 2000; 174: 1751-7.
[13]
Drent M, De Vries J, Lenters M, et al. Sarcoidosis: Assessment of disease severity using HRCT. Eur Radiol 2003; 13: 2462-71.
[14]
Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-53.
[15]
Keijsers RG, Verzijlbergen FJ, Oyen WJ, et al. 18F-FDG PET, genotypecorrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009; 36: 1131-7.
[16]
Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F-FDG PET/CT in sarcoidosis management: Review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35: 1537-43.
[17]
Keijsers RG, Van den Heuvel DAF, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J 2013; 41: 743-51.
[18]
Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: Sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging 2011; 55: 66-71.
[19]
Mostard RL, van Kroonenburgh MJ, Drent M. The role of the PET scan in the management of sarcoidosis. Curr Opin Pulm Med 2013; 19(5): 538-44.
[20]
Guleria R, Jyothidasan A, Madan K, et al. Utility of FDG-PET-CT scanning in assessing the extent of disease activity and response to treatment in sarcoidosis. Lung India 2014; 31(4): 323-30.
[21]
Treglia G, Taralli S, Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: A systematic review. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28(2): 87-94.
[22]
Soussan M, Augier A, Brillet PY, Weinmann P, Valeyre D. Functional imaging in extrapulmonary sarcoidosis: FDG-PET/CT and MR features. Clin Nucl Med 2014; 39(2): e146-59.
[23]
Bastiaannet E, Uyl-de Groot CA, Brouwers AH, et al. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. Ann Surg 2012; 255(4): 771-6.
[24]
Mana J, Salazar A, Manresa F. Clinical factors predicting persistence of activity in sarcoidosis: A multivariate analysis of 193 cases. Respiration 1994; 61(4): 219-25.
[25]
Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28(2): 123-9.
[26]
Takada K, Ina Y, Noda M, Sato T, Yamamoto M, Morishita M. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J Clin Epidemiol 1993; 46(4): 359-66.
[27]
Brincker H. Coexistence of sarcoidosis and malignant disease: Causality or coincidence? Sarcoidosis 1989; 6: 31-43.
[28]
Caetano R, Schluckebier LF, Bastos CR, et al. Cost analysis of18F-FDG PET-CT from the perspective of the Brazilian unified national health system as healthcare provider: A study in a public healthcare center in Rio de Janeiro, Brazil. Cad Saude Publica 2014; 30(2): 379-92.
[29]
Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: An observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25(2): 143-9.
[30]
Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 2005; 46(4): 608-13.
[31]
Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: Estimation of radiation dose and cancer risk. Radiology 2009; 251(1): 166-74.
[32]
Sobic-Saranovic D, Artiko V, Obradovic V. FDG PET imaging in sarcoidosis. Semin Nucl Med 2013; 43(6): 404-11.
[33]
Bichel J, Brincker H. Treatment of pruritus in Hodgkin’s disease and in reticulum cell sarcoma. Scand J Haematol 1965; 2: 85-90.
[34]
Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol 2005; 23: 4577-80.
[35]
JBasu S, Zhuang H, Torigian DA, et al Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med 2009; 39: 124-45.
[36]
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507.
[37]
Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002; 32: 47-59.
[38]
Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-9.
[39]
Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001; 28: 696-703.
[40]
Kaneko M, Tomioka H, Kaneda T, et al. Value of 18F-fluorodeoxyglucose-PET in the diagonosis and monitoring of pulmonary sarcoidosis: A case report. Nihon Kokyuki Gakkai Zasshi 2008; 46(6): 505-9.
[41]
Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998; 39: 1160-6.
[42]
Kis A, Eszes N, Tamasi L, et al. Sarcoidosis lymphoma syndrome - the value of PET-CT in the diagnosis. World J Surg Oncol 2013 18; 11: 235.
[43]
Brady B, Kamel D, Kiely J, Hennessy B. Dual diagnosis of sarcoidosis and lymphoma. Ir J Med Sci 2013; 182(2): 283-6.
[44]
Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation--current and emerging clinical applications. Clin Radiol 2015; 70(7): 787-800.
[45]
Grados A, Ebbo M, Bernit E, et al. Sarcoidosis occurring after solid cancer: A nonfortuitous association: Report of 12 cases and review of the literature. Medicine (Baltimore) 2015; 94(28): e928.
[46]
Chowdhury FU, Sheerin F, Bradley KM, Gleeson FV. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: Prevalence and disease pattern. Clin Radiol 2009; 64(7): 675-81.
[47]
Conte G, Zugni F, Colleoni M, Renne G, Bellomi M, Petralia G. Sarcoidosis with bone involvement mimicking metastatic disease at (18)F-FDG PET/CT: Problem solving by diffusion whole-body MRI. Ecancermedicalscience 2015 7; 9: 537..
[48]
Chen J, Carter R, Maoz D, Tobar A, Sharon E, Greif F. Breast cancer and sarcoidosis: Case series and review of the literature. Breast Care (Basel) 2015; 10(2): 137-40.
[49]
Tana C, Giamberardino MA, Di Gioacchino M, Mezzetti A, Schiavone C. Immunopathogenesis of sarcoidosis and risk of malignancy: a lost truth? Int J Immunopathol Pharmacol 2013; 26(2): 305-13.
[50]
Tchernev G, Chokoeva AA, Tana C, Patterson JW, Wollina U, Lotti T. Sarcoid sine sarcoidosis? A classificative, semantic and therapeutic dilemma. J Biol Regul Homeost Agents 2015; 29(1)(Suppl.): 33-4.
[51]
Tchernev G, Chokoeva AA, Tana M, Tana C. Transcriptional blood signatures of sarcoidosis, sarcoid-like reactions and tubercolosis and their diagnostic implications. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33(3): 5030.
41
2